NasdaqGS:TSHABiotechs
Taysha Gene Therapies (TSHA) Is Up 10.2% After Securing Long-Term TSHA-102 Manufacturing Capacity
Taysha Gene Therapies recently announced a commercial supply agreement under which Catalent will serve as the primary commercial manufacturer of TSHA-102, its investigational Rett syndrome gene therapy, at Catalent’s FDA-licensed facility in Harmans, Maryland, securing long-term GMP capacity to support potential U.S. launch and future demand.
This move effectively locks in a scalable manufacturing backbone for TSHA-102, signaling that Taysha is preparing its operations for possible...